Nanoscope Therapeutics Wins 'Best of Show' Award at AAO Eyecelerator 2023

Nanoscope Therapeutics was awarded the 'Best of Show in Retina' award at this year's American Academy of Ophthalmology (AAO) Eyecelerator conference. During the conference, Samuel Barone, MD, Nanoscope's chief medical officer, delivered a presentation titled "Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration." He unveiled clinical results from the company's optogenetic therapy, MCO-010, which targets inherited retinal diseases (IRDs) such as retinitis pigmentosa (RP) and Stargardt disease in a gene mutation agnostic fashion.

MCO-010, developed by Nanoscope Therapeutics co-founders Samarendra Mohanty, PhD, and Sulagna Bhattacharya, offers the potential to treat a multitude of ocular diseases by restoring light sensitivity to the retina and enhancing vision in patients with progressive and permanent photoreceptor and outer retinal degeneration.